Uncategorized

Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine

Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated consistently across age, gender, ethnicity and starting body mass index (BMI). Beneficial effects were seen consistently across measured cardiovascular endpoints with semaglutide 2.4 mg. Risk reductions in MACE were evident […]

Silk Road Medical Names Chas McKhann Chief Executive Officer

Accomplished Leader with Over 25 Years of Medical Device Industry Experience SUNNYVALE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road” or the “Company”), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed […]

Medtronic receives FDA approval for extravascular defibrillator to treat abnormal heart rhythms, sudden cardiac arrest

DUBLIN, Oct. 23, 2023 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV™ MRI SureScan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac […]

Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model

DURHAM, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced publication of a preclinical study showing the potential for its investigational small-diameter Human Acellular Vessel™ (HAV™) to treat Tetralogy of Fallot, a heart […]

Corsair Pharma Announces $23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension

SUNNYVALE, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) — Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced the closing of its $23M Series B financing led by New Rhein Healthcare Investors. Proceeds from the financing will support the clinical advancement of Corsair’s lead product candidate, […]

Forum Health Launches Groundbreaking AI Technology to Detect Signs of Heart Disease at an Earlier Stage

FLINT, Mich., Sept. 12, 2023 /PRNewswire/ — Forum Health Fond du Lac, a Forum Health national integrative and functional medicine network, has launched the Multifunction Cardiogram™ (MCG™) scan for early detection of heart disease and cardiac abnormalities. Learn more about the MCG™ scan. Unlike traditional methods that rely on symptom onset, the MCG™ scan […]

HighLife Launches a New Large Annulus Valve in Ongoing Clinical Studies for Patients Suffering From Mitral Regurgitation

PARIS–(BUSINESS WIRE)–HighLife SAS, a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe mitral regurgitation (MR), announced today the introduction of a new valve size in its clinical trials, the Large Annulus Valve (LAV), designed for […]

Elucid Appoints Windi Hary to Lead Regulatory Affairs and Quality Management

BOSTON–(BUSINESS WIRE)–Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Windi Hary as senior vice president (SVP) of regulatory affairs and quality management. Windi’s vast, global experience in software-as-a-medical device (SaMD) and AI-enabled digital health will be central to […]

Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)

NEW YORK, Aug. 30, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today announced the expanded evaluation of tecarfarin for the treatment […]